John J Atherton

John J Atherton

Director of Cardiology

Royal Brisbane and Women’s Hospital, Brisbane, AU

  • Radcliffe

Expertise

Biography

Dr John J. Atherton is a Sydney-born Australian cardiologist and clinician-scientist who has built his professional life in Brisbane, Queensland, where he currently serves as Director of Cardiology at the Royal Brisbane and Women’s Hospital. He practices adult cardiology with a focus on heart failure and advanced cardiovascular disease, and lives in Brisbane while maintaining academic appointments across multiple universities in Queensland.

 

Academic History

Dr Atherton earned his medical degree (MBBS) in Australia and completed specialist training in cardiology, achieving membership of the Royal Australasian College of Physicians (FRACP) and advanced fellowships in cardiology. His academic roles include Professor in the Faculty of Medicine at the University of Queensland and Adjunct Professor in the Faculty of Health at the Queensland University of Technology.

He completed a PhD focused on symptom interventions and self-management in chronic cardiac disease, and he has since contributed extensively to cardiovascular research, particularly in early detection of heart disease and optimisation of heart failure care.

 

Career Overview

Dr Atherton is Director of Cardiology at the Royal Brisbane and Women’s Hospital, where he leads clinical services, research programs and statewide initiatives in heart failure management across Queensland. He has served as an appointed member of the Australian Government Medical Services Advisory Committee, providing expert advice on Medicare and national health funding arrangements.

His past leadership roles include serving on the Board of the Cardiac Society of Australia and New Zealand, chairing the Asia-Pacific Acute Decompensated Heart Failure Registry Scientific Advisory Committee, and chairing the CSANZ Heart Failure Council.

Dr Atherton was also a major contributor to the 2018 National Heart Foundation of Australia and CSANZ Heart Failure Guidelines, and served as a non-European content reviewer for the 2016 European Society of Cardiology Heart Failure Guidelines.

He is the Data Custodian for the Queensland Cardiac Outcomes Registry – Heart Failure, serves on the National Cardiac Registry Board, and contributes to multiple national advisory committees in cardiovascular medicine. He is also Associate Editor for Heart, Lung and Circulation and an Editorial Board Member for Cardiac Failure Review.

 

Career Timeline

Early Career: Completed specialist cardiology training and PhD research.

2003–present: Member, Australian Government Medical Services Advisory Committee.

2009–2015: Board Member, Cardiac Society of Australia and New Zealand (CSANZ).

2016: Non-European Content Reviewer, European Society of Cardiology Heart Failure Guidelines.

2018: Chair, National Heart Foundation of Australia/CSANZ Heart Failure Guidelines.

Recent: Director of Cardiology at Royal Brisbane and Women’s Hospital; Data Custodian for QCOR Heart Failure; National Cardiac Registry Board Director.

 

Recognition

Dr Atherton is widely recognised for his contributions to heart failure research, clinical guideline development and cardiac service improvement. His leadership has helped shape national policy, registry development and evidence-based cardiovascular care throughout Australia. His editorial work and extensive scientific publications further reflect his standing as a leading figure in heart failure and clinical cardiology.

 

Areas of Speciality

  • Heart Failure
  • Pre-symptomatic Heart Disease Detection
  • Cardiac Genetics
  • Hypertrophic Cardiomyopathy
  • Cardiovascular Clinical Registries
  • Heart Failure Disease Management
  • Health Service Improvement in Cardiology

 

Sources

Articles by John J Atherton, Director of Cardiology

Is Medication Titration in Heart Failure too Complex?

John J Atherton, Annabel Hickey,

Citation: Cardiac Failure Review 2017;3(1):25–32.

Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?

Sam Hayman, John J Atherton,

Citation: Cardiac Failure Review 2016;2(1):47–50